Rademikibart: Expiry of patents related to composition-of-matter in June 2037 (Connect Biopharma) - May 27, 2025 - Corporate Presentation: Expiry of patents related to formulation in March 2040; Biologic exclusivity until 2040; Patent term extension until 2042
Commercial • Patent • Asthma • Chronic Obstructive Pulmonary Disease • Immunology
|